New generation obesity treatment on the way
Summary
GP Brian Higgins discusses Eli Lilly's new obesity drug, retatrutide, which outperforms Ozempic by adding glucagon to increase calorie burn. The conversation covers the evolution of incretin therapies, the importance of resistance exercise to prevent muscle loss, and the dangers of purchasing unregulated drugs online. Higgins also highlights potential side effects, including severe nausea and skin tingling, that may limit patient tolerance.
Topics discussed
Intro: Retatrutide outperforms Ozempic
Explanation of incretins and GLP-1/GIP
Evolution from Liraglutide to Semaglutide
Tirzepatide and appetite suppression mechanism
Retatrutide's unique glucagon component
Weight loss results vs gastric surgery
Risks of unsupervised use and muscle loss
Black market drugs and bodybuilder usage
Starvation mode and muscle preservation
Bodybuilder competition cycles and deficits
Side effects: Nausea and GIP mitigation
New side effects and closing remarks
Listen ad-free on Castria